International sellers are hiking shipping fees as U.S. tariffs spark confusion, surprise charges, and threaten billions in export revenues.
Author: Democratically
Moderna’s reformulated Spikevax achieves an eightfold surge in antibodies against a key COVID-19 variant, but political and economic hurdles threaten progress.
Eli Lilly’s weight-loss pill is on the FDA’s fast-track, but a recent warning over misleading safety claims casts new light on the race to make obesity drugs safer, faster, and more affordable.
Trump’s executive orders promise lower drug prices, but as global pharma reels and oversight erodes, who really benefits?
Brandeis is betting $25 million on a future-focused, equitable model for higher education as traditional colleges face closure and political attacks threaten diversity and access.
Alphabet’s $3 trillion breakthrough exposes the tension between tech progress and unchecked corporate concentration—what does this mean for democracy and innovation?
John Oliver’s Emmy win spotlights the rising pressure on late-night satire—and the networks eager to control what you hear.
Buttigieg’s candid criticism of Biden’s 2024 campaign exposes Democratic divisions and raises urgent questions about party accountability.
A closer look at how the mass detention of Korean workers in Georgia exposed weaknesses in U.S. immigration policy and tested the resilience of the U.S.–South Korea alliance.
A suspended nurse sues after confronting a doctor’s incendiary remarks about Charlie Kirk—triggering a fierce debate over ethics, whistleblower rights, and hospital culture.